|
|
4d Molecular Therapeutics Inc (NASDAQ: FDMT) |
|
Overall company Market Share Q1 2025 |
*Market share is calculated based on total revenue.
News about 4d Molecular Therapeutics Inc Contracts |
August 27, 2024
Emeryville, Calif., August 27, 2024 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading clinical-stage genetic medicines company, has announced its plans to host a 4D-150 Wet AMD Development Day on September 18, 2024, at 4:15 p.m. ET. This significant event underscores 4DMT s commitment to advancing innovative genetic treatments for large market diseases, particularly through its promising candidate, 4D-150, aimed at treating wet age-related macular degeneration (wet AMD).This upcoming Development Day will serve as a deep dive into the progress and future prospects of 4D-150, a cutting-edge intravitreal gene therapy. Wet AMD is a prevalent and severe eye condition that causes vision ...
|
May 30, 2024
4D Molecular Therapeutics (4DMT), a renowned genetic medicines company, has recently shared exciting news about the interim data from its Phase 1/2 AEROW clinical trial for aerosolized 4D-710, a potential breakthrough treatment for cystic fibrosis (CF) lung disease. The company announced that the data will be presented at the upcoming 47th European Cystic Fibrosis Conference taking place in Glasgow, UK. This highly anticipated presentation will shed light on the potential of 4D-710 to revolutionize the treatment landscape for CF patients. In addition, 4DMT will organize a webcast to discuss the details of the data and provide an update on their program.Background:Cystic fibrosis is a life-threatening genetic...
|
March 28, 2024
In recent years, genetic medicine has emerged as a groundbreaking field in the fight against numerous diseases. Among these diseases, Cystic Fibrosis (CF) has posed significant challenges due to its complex genetic nature. However, there is a new ray of hope with the development of 4D-710, an aerosolized genetic medicine by 4D Molecular Therapeutics (4DMT). The company has recently provided an update on its regulatory interactions and development path for this promising treatment, indicating exciting progress in tackling CF lung disease.4D-710: A Glimpse into the Future of CF Treatment:4D-710 is an aerosolized genetic medicine specifically engineered to target and correct the underlying genetic mutations res...
|
February 12, 2024
4D Molecular Therapeutics (4DMT), a pioneering clinical-stage genetic medicines company, shared updated interim safety and efficacy data on their investigational therapy, 4D-310, for the treatment of Fabry disease cardiomyopathy. The data were presented at the prestigious WORLD Symposium 2024 in San Diego, California. Fabry disease is a rare genetic disorder characterized by the accumulation of a lipid called globotriaosylceramide (GL-3) within various organs, leading to life-threatening complications.Promising Results for Fabry Disease Cardiomyopathy Treatment:The study included six adult patients with Fabry disease cardiomyopathy who received a single intravenous infusion of 4D-310 at a dose of 1E13 vector...
|
Publicly Traded Peers of 4d Molecular Therapeutics Inc
Passage Bio Inc
Share Performance
-29.50%
This Quarter
|
Passage Bio Inc
Profile
Passage Bio Inc's business model focuses on developing and commercializing innovative genetic therapies for rare, monogenic central nervous system disorders.
More about Passage Bio Inc 's Market Share
|
Bluebird Bio Inc
Share Performance
+22.30%
This Quarter
|
Bluebird Bio Inc
Profile
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
More about Bluebird Bio Inc 's Market Share
|
Regenxbio Inc
Share Performance
+23.54%
This Year
|
Regenxbio Inc
Profile
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
More about Regenxbio Inc 's Market Share
|
Editas Medicine Inc
Share Performance
+4.03%
Over The Past 5 Days
|
Editas Medicine Inc
Profile
Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.
More about Editas Medicine Inc 's Market Share
|
Sarepta Therapeutics Inc
Share Performance
-69.46%
This Year
|
Sarepta Therapeutics Inc
Profile
Sarepta Therapeutics Inc's business model centers around the research, development, and commercialization of innovative genetic medicines for rare diseases, with a particular focus on Duchenne muscular dystrophy (DMD).
More about Sarepta Therapeutics Inc 's Market Share
|
Intellia Therapeutics Inc
Share Performance
-24.73%
This Quarter
|
Intellia Therapeutics Inc
Profile
Intellia Therapeutics Inc is a biotechnology company focused on developing therapies based on CRISPR/Cas9 gene editing technology.
More about Intellia Therapeutics Inc 's Market Share
|
Crispr Therapeutics Ag
Share Performance
-11.03%
This Year
|
Crispr Therapeutics Ag
Profile
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
More about Crispr Therapeutics Ag's Market Share
|
Sangamo Therapeutics Inc
Share Performance
-58.12%
This Year
|
Sangamo Therapeutics Inc
Profile
Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients' lives.
More about Sangamo Therapeutics Inc 's Market Share
|
Krystal Biotech Inc
Share Performance
-5.47%
Over The Past 5 Days
|
Krystal Biotech Inc
Profile
Krystal Biotech Inc's business model focuses on developing and commercializing gene therapies.
More about Krystal Biotech Inc 's Market Share
|
Prime Medicine Inc
Share Performance
-81.37%
One Year
|
Prime Medicine Inc
Profile
Prime Medicine Inc is a biotechnology company specializing in gene editing technologies and therapeutics. Their business model revolves around harnessing advanced CRISPR-based gene editing techniques to develop treatments for genetic diseases. By using innovative science and strategic partnerships, the company aims to bring transformative therapies to patients in need.
More about Prime Medicine Inc 's Market Share
|
Caribou Biosciences Inc
Share Performance
-2.86%
Over The Past 5 Days
|
Caribou Biosciences Inc
Profile
Caribou Biosciences Inc is a biotechnology company that focuses on the development of gene editing technologies. Their business model involves licensing their proprietary CRISPR-Cas9 platform and collaborating with partners to advance research and therapeutic applications in various industries.
More about Caribou Biosciences Inc 's Market Share
|
Ginkgo Bioworks Holdings Inc
Share Performance
-31.60%
This Year
|
Ginkgo Bioworks Holdings Inc
Profile
Ginkgo Bioworks Holdings Inc is a biotechnology company that focuses on using genetic engineering to develop new organisms for various industries. Their business model includes partnering with companies to create custom-designed organisms for applications such as fragrance production, food and beverage, agriculture, and pharmaceuticals. They generate revenue through collaborations, licensing agreements, and providing access to their platform for organism design and development.
More about Ginkgo Bioworks Holdings Inc 's Market Share
|
Jasper Therapeutics Inc
Share Performance
-80.06%
One Year
|
Jasper Therapeutics Inc
Profile
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
More about Jasper Therapeutics Inc's Market Share
|
Precision Biosciences Inc
Share Performance
-22.77%
This Quarter
|
Precision Biosciences Inc
Profile
Precision Biosciences Inc operates under a business model focused on gene editing. They develop and commercialize its ARCUS genome editing platform to create innovative therapies for genetic diseases and cancer. The company offers its gene editing capabilities to partners and collaborates on various research and development projects.
More about Precision Biosciences Inc's Market Share
|
Sqz Biotechnologies Company
Share Performance
-6.67%
This Year
|
Sqz Biotechnologies Company
Profile
Sqz Biotechnologies Company's business model revolves around developing and commercializing innovative cell engineering platforms for multiple applications across the healthcare industry.
More about Sqz Biotechnologies Company's Market Share
|
Beam Therapeutics Inc
Share Performance
-16.56%
30 Days
|
Beam Therapeutics Inc
Profile
Beam Therapeutics Inc's business model revolves around developing precision genetic medicines using base editing technology. They aim to address genetic diseases by making precise edits to a patient's DNA at the molecular level, providing potential treatments that are highly targeted and minimally invasive.
More about Beam Therapeutics Inc 's Market Share
|
Century Therapeutics inc
Share Performance
-46.27%
This Year
|
Century Therapeutics inc
Profile
Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.
More about Century Therapeutics inc 's Market Share
|
Omega Therapeutics Inc
Share Performance
-32.45%
Over The Past 5 Days
|
Omega Therapeutics Inc
Profile
Omega Therapeutics Inc is a biotechnology company that focuses on developing therapies by leveraging the power of epigenetics. Their business model involves utilizing their proprietary Omega Epigenomic Programming technology to target specific genes and modulate their activity, addressing complex diseases at their source. By creating innovative and precise therapeutic interventions, Omega Therapeutics aims to make significant advancements in healthcare.
More about Omega Therapeutics Inc 's Market Share
|
Black Diamond Therapeutics Inc
Share Performance
-58.90%
One Year
|
Black Diamond Therapeutics Inc
Profile
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
More about Black Diamond Therapeutics Inc 's Market Share
|
Poseida Therapeutics Inc
Share Performance
+194.12%
One Year
|
Poseida Therapeutics Inc
Profile
Poseida Therapeutics Inc's business model revolves around developing and commercializing gene therapies for a wide range of diseases and conditions.
More about Poseida Therapeutics Inc 's Market Share
|
Sana Biotechnology Inc
Share Performance
+12.43%
30 Days
|
Sana Biotechnology Inc
Profile
Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.
More about Sana Biotechnology Inc 's Market Share
|
Cargo Therapeutics Inc
Share Performance
+8.75%
This Quarter
|
Cargo Therapeutics Inc
Profile
Cargo Therapeutics Inc is a biotechnology company that utilizes a unique business model focused on developing targeted therapeutics. Their approach involves engineering cell-penetrating peptides to deliver various cargoes, such as gene therapies or small molecules, directly to specific cells or tissues, increasing precision and effectiveness of treatments. By leveraging this technology, the company aims to address unmet medical needs with potentially transformative therapies.
More about Cargo Therapeutics Inc 's Market Share
|
Pluri Inc
Share Performance
+3.95%
This Year
|
Pluri Inc
Profile
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
More about Pluri Inc's Market Share
|
Biontech Se
Share Performance
-17.77%
This Quarter
|
Biontech Se
Profile
Biontech SE's business model focuses on the development and commercialization of novel mRNA-based immunotherapies for various diseases, including cancer.
More about Biontech Se's Market Share
|
Orchard Therapeutics Plc
Share Performance
+1.71%
This Year
|
Orchard Therapeutics Plc
Profile
Orchard Therapeutics Plc operates as a biotechnology company specializing in gene therapies for rare diseases. Their business model involves developing and commercializing potentially curative gene therapies to address the underlying cause of these diseases. They collaborate with academic and industry partners to advance their research and utilize their expertise to bring innovative therapies to patients in need.
More about Orchard Therapeutics Plc's Market Share
|
Contextlogic Inc
Share Performance
+4.11%
This Quarter
|
Contextlogic Inc
Profile
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
More about Contextlogic Inc 's Market Share
|
Taysha Gene Therapies Inc
Share Performance
-15.12%
One Year
|
Taysha Gene Therapies Inc
Profile
Taysha Gene Therapies Inc operates under a business model focused on developing and commercializing innovative genetic therapies to treat and potentially cure patients with rare monogenic diseases. Utilizing cutting-edge technologies, the company aims to bring transformative treatments to market in order to improve the lives of individuals suffering from these rare genetic disorders.
More about Taysha Gene Therapies Inc 's Market Share
|
Cyclo Therapeutics Inc
Share Performance
-10.14%
30 Days
|
Cyclo Therapeutics Inc
Profile
Cyclo Therapeutics Inc is a biotechnology company that focuses on developing innovative treatments for rare and life-threatening diseases. Their business model involves conducting research, developing therapeutic solutions using their proprietary technology, and eventually commercializing these therapies through partnerships or direct sales.
More about Cyclo Therapeutics Inc 's Market Share
|
Axcella Health Inc
Share Performance
-59.87%
30 Days
|
Axcella Health Inc
Profile
Axcella Health Inc is a biotechnology company that operates with a novel business model. They focus on discovering and developing Endogenous Metabolic Modulators (EMMs) as potential therapeutics for various diseases. Their approach revolves around leveraging the body's natural metabolic pathways to address unmet medical needs, with an emphasis on designing EMM compositions that can impact multiple targets simultaneously.
More about Axcella Health Inc 's Market Share
|
Applied Genetic Technologies Corporation
Share Performance
-7.45%
This Quarter
|
Applied Genetic Technologies Corporation
Profile
Applied Genetic Technologies Corporation (AGTC) is a biotechnology company that focuses on developing gene therapies to treat rare genetic diseases. They utilize their proprietary technology platform to design and develop novel treatments targeting specific genetic disorders. AGTC primarily operates by collaborating with strategic partners and conducting clinical trials to advance their gene therapy candidates towards commercialization.
More about Applied Genetic Technologies Corporation's Market Share
|
Eiger Biopharmaceuticals Inc
Share Performance
-75.57%
This Year
|
Eiger Biopharmaceuticals Inc
Profile
Eiger Biopharmaceuticals Inc is a biotechnology company focused on developing and commercializing innovative therapies for serious rare and ultra-rare diseases.
More about Eiger Biopharmaceuticals Inc 's Market Share
|
Protalix Biotherapeutics inc
Share Performance
-17.77%
This Year
|
Protalix Biotherapeutics inc
Profile
Protalix Biotherapeutics Inc. operates under a business model focused on the development, production, and commercialization of recombinant therapeutic proteins using plant cell culture technology, aiming to address unmet medical needs and provide innovative treatment options to patients worldwide.
More about Protalix Biotherapeutics inc 's Market Share
|
Atara Biotherapeutics Inc
Share Performance
-6.05%
30 Days
|
Atara Biotherapeutics Inc
Profile
Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.
More about Atara Biotherapeutics Inc 's Market Share
|
Prokidney Corp
Share Performance
-28.24%
30 Days
|
Prokidney Corp
Profile
Prokidney Corp is a medical device company that specializes in developing innovative solutions for kidney dialysis treatment. Their business model focuses on designing, manufacturing, and marketing advanced dialysis machines and related consumables to healthcare providers worldwide. Through strategic partnerships and collaborations, Prokidney Corp aims to improve patient outcomes and enhance the overall efficiency of kidney dialysis procedures.
More about Prokidney Corp 's Market Share
|
Vor Biopharma Inc
Share Performance
-75.72%
30 Days
|
Vor Biopharma Inc
Profile
Vor Biopharma Inc's business model focuses on developing novel cell therapies for the treatment of cancer.
More about Vor Biopharma Inc 's Market Share
|
Allogene Therapeutics Inc
Share Performance
-51.15%
This Quarter
|
Allogene Therapeutics Inc
Profile
Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.
More about Allogene Therapeutics Inc 's Market Share
|
Genenta Science S p a
Share Performance
+7.14%
30 Days
|
Genenta Science S p a
Profile
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
More about Genenta Science S p a 's Market Share
|
Autolus Therapeutics Plc
Share Performance
-60.71%
One Year
|
Autolus Therapeutics Plc
Profile
Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.
More about Autolus Therapeutics Plc's Market Share
|
Meiragtx Holdings Plc
Share Performance
-3.50%
One Year
|
Meiragtx Holdings Plc
Profile
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
More about Meiragtx Holdings Plc's Market Share
|
Replimune Group Inc
Share Performance
-40.27%
This Quarter
|
Replimune Group Inc
Profile
Replimune Group Inc has a business model centered around the development of oncolytic immunotherapies.
More about Replimune Group Inc 's Market Share
|
Relay Therapeutics Inc
Share Performance
-25.77%
This Quarter
|
Relay Therapeutics Inc
Profile
Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.
More about Relay Therapeutics Inc 's Market Share
|
Lexeo Therapeutics Inc
Share Performance
-14.29%
Over The Past 5 Days
|
Lexeo Therapeutics Inc
Profile
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
More about Lexeo Therapeutics Inc 's Market Share
|
Cabaletta Bio Inc
Share Performance
-15.05%
This Quarter
|
Cabaletta Bio Inc
Profile
Cabaletta Bio Inc's business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.
More about Cabaletta Bio Inc 's Market Share
|
Tourmaline Bio Inc
Share Performance
+13.90%
One Year
|
Tourmaline Bio Inc
Profile
Tourmaline Bio Inc's business model revolves around the development and commercialization of innovative healthcare solutions.
More about Tourmaline Bio Inc 's Market Share
|
Ocugen Inc
Share Performance
+20.91%
Over The Past 5 Days
|
Ocugen Inc
Profile
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
More about Ocugen Inc 's Market Share
|
Uniqure N v
Share Performance
-16.01%
This Year
|
Uniqure N v
Profile
Uniqure N.V's business model revolves around developing and commercializing gene therapies to address rare genetic diseases.
More about Uniqure N v 's Market Share
|
Sources: 4d Molecular Therapeutics Inc and all companies mentioned above in this report
|
